Evidence map›Paper›PMID 32093290›Full record

ArticleInternational journal of molecular sciences2020

Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.

Shih-Han Chen, Jui-Ming Sun, Bing-Mao Chen, Sheng-Che Lin, Hao-Fang Chang, Sara Collins, Deching Chang, Shu-Fen Wu, Yin-Che Lu, Weijun Wang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Shih-Han ChenSection of Neurosurgery, Department of Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi 600, Taiwan.
Jui-Ming SunSection of Neurosurgery, Department of Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi 600, Taiwan.
Bing-Mao ChenDepartment of Biomedical Sciences, National Chung Cheng University, Chia-Yi 621, Taiwan.
Sheng-Che LinDepartment of Biomedical Sciences, National Chung Cheng University, Chia-Yi 621, Taiwan.
Hao-Fang ChangDepartment of Biomedical Sciences, National Chung Cheng University, Chia-Yi 621, Taiwan.
Sara CollinsDepartment of Neurological Surgery, University of California, San Francisco, CA 94143, USA.
Deching ChangDepartment of Biomedical Sciences, National Chung Cheng University, Chia-Yi 621, Taiwan.
Shu-Fen WuDepartment of Biomedical Sciences, National Chung Cheng University, Chia-Yi 621, Taiwan.
Yin-Che LuDepartment of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan 717, Taiwan.
Weijun WangDepartment of Neurosurgery, University of Southern California, Los Angeles, CA 90033, USA.
Thomas C ChenDepartment of Neurosurgery, University of Southern California, Los Angeles, CA 90033, USA.
Noriyuki KasaharaDepartment of Neurological Surgery, University of California, San Francisco, CA 94143, USA.
Hsin-Ell WangDepartment of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei 112, Taiwan.
Chien-Kuo TaiDepartment of Biomedical Sciences, National Chung Cheng University, Chia-Yi 621, Taiwan.ORCID 0000-0001-8775-6115
National Chung Cheng University · TWUniversity of California, San Francisco · USUniversity of Southern California · USAsia University · TWChia Nan University of Pharmacy and Science · TWChia-Yi Christian Hospital · TWNational Yang Ming Chiao Tung University · TW

Funding

Ditmanson Medical Foundation Chia-Yi Christian Hospital R104-001Ministry of Science and Technology, Taiwan 104-2320-B-194-004
6 · The paper itself

Abstract

Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma cells both in culture and in vivo. To avoid receptor interference and enable dual vector co-infection with MLV-RRV, we have developed another RRV based on gibbon ape leukemia virus (GALV) that also shows robust replicative spread in a wide variety of tumor cells. We evaluated the potential of GALV-based RRV as a cancer therapeutic agent by incorporating yeast cytosine deaminase (CD) and

Indexed as

Genetic TherapyGenetic VectorsAnimalsAziridinesBrain NeoplasmsCell Line, TumorCytosine DeaminaseEscherichia coli ProteinsFlucytosineGliomaLeukemia Virus, Gibbon ApeNeoplasms, ExperimentalNitroreductasesProdrugsRats, Inbred F344Saccharomyces cerevisiae ProteinsAziridinesCytosine DeaminaseEscherichia coli ProteinsFlucytosineNfsA protein, E coliNitroreductasesProdrugsSaccharomyces cerevisiae Proteinstretazicarbrain tumorE. coli nitroreductase genegene therapyprodrug activatorretroviral replicating vector

Identifiers

PMID32093290
PMCPMC7073086
OpenAlexW3007832012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.